Tags

Type your tag names separated by a space and hit enter

Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.
J Clin Psychopharmacol. 2016 Feb; 36(1):63-70.JC

Abstract

BACKGROUND

In the last 10 years, dopamine replacement therapy (DRT) has become a well-known risk factor for developing an impulse control disorder, such as gambling disorder (GD). Another medication, aripiprazole (ARI), has been more recently identified as another risk factor. Dopamine replacement therapy and ARI share a dopamine agonist action. Our work aimed at comparing patients with PG according to their treatment with DRT or ARI.

METHODS

Two methods were combined-a systematic review concentrated on case reports and the analysis of a French disordered gamblers cohort focused on patients using ARI or DRT at inclusion.

RESULTS

We reported 48 cases of GD possibly due to DRT and 17 cases of GD possibly due to ARI. Because of their standardized assessment, only the EVALJEU patients could be compared. Two clinical patterns emerged. Patients in the ARI group were young, impulsive, and high novelty seekers and had a history of substance misuse. Their first gambling experience occurred during adolescence. Conversely, patients in the DRT group were old, and they began gambling late in life. They showed low levels of gambling-related cognition.

CONCLUSIONS

Patients in the ARI group seemed to be more severe pathological gamblers than patients in the DRT group. Aripiprazole is a partial D2 receptor agonist, whereas DRT includes full D2 receptor agonist. The trigger mechanism of PG development is complex and cannot only be attributed only to the pharmacodynamic effects of dopaminergic drugs. Indeed, individual vulnerability factors and environmental factors need to be considered.

Authors+Show Affiliations

From the *Clinical Investigation Unit, "Behavioral Addictions/Complex Affective Disorders," Department of Addictology and Psychiatry, CHU Nantes; †EA 4275 "Biostatistics, Pharmacoepidemiology, and Subjective Measures in Health Sciences," Université Nantes; Departments of ‡Pharmacology, and §Neurology, CHU Nantes, Nantes, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review

Language

eng

PubMed ID

26658263

Citation

Grall-Bronnec, Marie, et al. "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? a Review." Journal of Clinical Psychopharmacology, vol. 36, no. 1, 2016, pp. 63-70.
Grall-Bronnec M, Sauvaget A, Perrouin F, et al. Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. J Clin Psychopharmacol. 2016;36(1):63-70.
Grall-Bronnec, M., Sauvaget, A., Perrouin, F., Leboucher, J., Etcheverrigaray, F., Challet-Bouju, G., Gaboriau, L., Derkinderen, P., Jolliet, P., & Victorri-Vigneau, C. (2016). Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. Journal of Clinical Psychopharmacology, 36(1), 63-70. https://doi.org/10.1097/JCP.0000000000000444
Grall-Bronnec M, et al. Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? a Review. J Clin Psychopharmacol. 2016;36(1):63-70. PubMed PMID: 26658263.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. AU - Grall-Bronnec,Marie, AU - Sauvaget,Anne, AU - Perrouin,Fanny, AU - Leboucher,Juliette, AU - Etcheverrigaray,François, AU - Challet-Bouju,Gaëlle, AU - Gaboriau,Louise, AU - Derkinderen,Pascal, AU - Jolliet,Pascale, AU - Victorri-Vigneau,Caroline, PY - 2015/12/15/entrez PY - 2015/12/15/pubmed PY - 2016/9/27/medline SP - 63 EP - 70 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 36 IS - 1 N2 - BACKGROUND: In the last 10 years, dopamine replacement therapy (DRT) has become a well-known risk factor for developing an impulse control disorder, such as gambling disorder (GD). Another medication, aripiprazole (ARI), has been more recently identified as another risk factor. Dopamine replacement therapy and ARI share a dopamine agonist action. Our work aimed at comparing patients with PG according to their treatment with DRT or ARI. METHODS: Two methods were combined-a systematic review concentrated on case reports and the analysis of a French disordered gamblers cohort focused on patients using ARI or DRT at inclusion. RESULTS: We reported 48 cases of GD possibly due to DRT and 17 cases of GD possibly due to ARI. Because of their standardized assessment, only the EVALJEU patients could be compared. Two clinical patterns emerged. Patients in the ARI group were young, impulsive, and high novelty seekers and had a history of substance misuse. Their first gambling experience occurred during adolescence. Conversely, patients in the DRT group were old, and they began gambling late in life. They showed low levels of gambling-related cognition. CONCLUSIONS: Patients in the ARI group seemed to be more severe pathological gamblers than patients in the DRT group. Aripiprazole is a partial D2 receptor agonist, whereas DRT includes full D2 receptor agonist. The trigger mechanism of PG development is complex and cannot only be attributed only to the pharmacodynamic effects of dopaminergic drugs. Indeed, individual vulnerability factors and environmental factors need to be considered. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/26658263/Pathological_Gambling_Associated_With_Aripiprazole_or_Dopamine_Replacement_Therapy:_Do_Patients_Share_the_Same_Features_A_Review_ L2 - https://doi.org/10.1097/JCP.0000000000000444 DB - PRIME DP - Unbound Medicine ER -